New Paper- Intranasal VIP safely restores volume to multiple grey matter nuclei in patients with CIRS


New Paper- Intranasal VIP safely restores volume to multiple grey matter nuclei in patients with CIRS
Abstract:
Evidence has accumulated since 2008 that intranasal, topical application of vasoactive intestinal polypeptide (VIP) can be administered safely to patients with a multi-system, multisymptom illness, called chronic inflammatory response syndrome (CIRS), acquired following exposure to biologically produced toxins and inflammagens. To date, over 300 physicians have prescribed intranasal VIP for their CIRS patients; these physicians have overwhelmingly (>90%) reported intranasal VIP to reduce symptoms; reduce elevated levels of MMP9, TGF beta-1 and C4a; raise low levels of VEGF; normalize clotting abnormalities, including acquired von Willebrand’s; and return regulation to pituitary systemic axes involving ACTH/cortisol and ADH/osmolality. These changes did not occur without use of VIP, though antecedent steps in a sequential treatment protocol provided benefit for many patients. The mechanism of these salutary health effects provided by VIP likely involves correction of abnormalities in ribosomal gene activation, nuclear encoded mitochondrial gene activation and an upregulation of Ikaros, a zinc fingered transcription factor. Recent preliminary work using sequential measurement of CNS volumes by NeuroQuant showed a longer treatment window (> 12 weeks) and higher doses of VIP (> 6 doses/day) safely corrected multinuclear atrophy of grey matter. The current study built upon this preliminary work and identified a course of VIP treatment that restores grey matter nuclear atrophy in CIRS patients. Safety of VIP and durability of benefit were both shown with no significant adverse effects reported by any patients.
 

Comments

No comments have been posted yet.


Featured Resources

image description

EMSL lab director acknowledges EPA investigation; offers free repeat ERMI Share on Twitter Like on Facebook Share on Google+ Share on Twitter Like on Facebook Share on Google+

Beginning in late spring 2015, physicians from the Professionals Panel of Surviving Mold noted that something was odd with a variety of Environmental Relative Moldiness Index (ERMI) reports. A number of labs, including EMSL, appeared to not report low leve...

image description

Dr. Joseph Brewer: Nasal Fungi, Anti-Fungals and Junk Science Share on Twitter Like on Facebook Share on Google+ Share on Twitter Like on Facebook Share on Google+

In 2005, at the height of viciousness of mold litigation, defense interests loved using a California idea (“Geffcken”) that held that if a plaintiff couldn’t show the presence of the same mycotoxins in his body that were found in a wet building, then ...

image description

Dr. Shoemaker on IAQ Radio March 3, 2017 Share on Twitter Like on Facebook Share on Google+ Share on Twitter Like on Facebook Share on Google+

Ritchie Shoemaker, MD The Union of Genomics and NeuroQuant

image description

NeuroQuant Paper Announcement Share on Twitter Like on Facebook Share on Google+ Share on Twitter Like on Facebook Share on Google+

The Center for Research on Biotoxin Associated Illnesses of Pocomoke, Maryland is pleased to announce that its newest academic paper entitled “Structural brain abnormalities in patients with inflammatory illness acquired following exposure to water-damage...

image description

As I See It- EPA’s Office of Inspector General (OIG) suddenly claims the agency’s intellectual property, a published, patented and licensed product, ERMI, has not been validated for public use Share on Twitter Like on Facebook Share on Google+ Share on Twitter Like on Facebook Share on Google+

Numerous errors (at least 27) of logic aside, we see no evidence that the OIG is competent to discuss the issue in the first place. Patient safety and human health will suffer as a result of this wrong-headed opinion on indoor environments.

Related Resources